Who to call at Celosia Therapeutics, and when
Fundz watches for the moments Celosia Therapeutics starts buying, and tells you who to reach.
- An alert the day Celosia Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Celosia Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Celosia Therapeutics. With Fundz connected, it knows.
Celosia Therapeutics, a Macquarie University spinout developing gene therapies for motor neurone disease, secured a $2 million grant from NSW government's Emerging Technology Commercialisation Fund.
Description
Celosia Therapeutics has been awarded a $2 million grant from the NSW government's new Emerging Technology Commercialisation Fund, the largest grant in the first round of the program. The funding will support expansion of Celosia's MND pipeline, including candidate development, manufacturing work, and preclinical studies for its lead program CTx1000. Celosia will collaborate with the NSW Viral Vector Manufacturing Facility over two years to develop manufacturing processes for a new gene therapy candidate. The biotech, which previously raised $16.75 million in a Series A round in 2024, is developing treatments for motor neurone disease based on research into the TDP-43 protein.
Quick answer
Celosia Therapeutics, a Macquarie University spinout developing gene therapies for motor neurone disease, secured a $2 million grant from NSW government's Emerging Technology Commercialisation Fund. (November 18, 2026). Celosia Therapeutics is based in New South Wales, Australia.
- What agreement did Celosia Therapeutics announce on November 18, 2026?
- Celosia Therapeutics has been awarded a $2 million grant from the NSW government's new Emerging Technology Commercialisation Fund, the largest grant in the first round of the program. The funding will support expansion of Celosia's MND pipeline, including candidate development, manufacturing work, and preclinical studies for its lead program CTx1000.
- What does Celosia Therapeutics do?
- Celosia Therapeutics is a Macquarie University spinout developing gene therapies for motor neurone disease (MND), specifically amyotrophic lateral sclerosis (ALS).
- Where is Celosia Therapeutics based?
- Celosia Therapeutics is based in New South Wales, Australia.
- Which similar companies announced agreements around the same time?
- AstraZeneca Pharma India (November 17, 2026), Innate Pharma (November 15, 2026), Pfizer (November 14, 2026) and Sino Biopharmaceutical (November 13, 2026) also announced agreements within 45 days of Celosia Therapeutics.
Source: Fundz verified event record.
Other recent agreements in Therapeutics and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- AstraZeneca Pharma India Forms Partnership with Strand Life Sciences for Healthcare Collaboration. (November 17, 2026)
- Innate Pharma and Sobi Partnership Now Effective with $75 Million Upfront Payment (November 15, 2026)
- Pfizer Partners with Blackstone Life Sciences to Co-Fund $1.5 Billion Development for Berobenatide Obesity Drug. (November 14, 2026)
- Sino Biopharmaceutical Partners with Boehringer Ingelheim in a $358 Million Oncology Deal (November 13, 2026)
- Ocugen Enters Exclusive License Agreement with Celairis Therapeutics (November 10, 2026)
- Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment. (November 5, 2026)
Celosia Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.